ArticleFrontiers in pharmacology2015
Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective.
Article in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 3 syntheses or guidelines pooled it, 362 citations in OpenAlex.
- Meta-analysis and review of in silico methods in drug discovery - part 1: technological evolution and trends from big data to chemical space.The pharmacogenomics journal · 2025Pooled it
- TRAF6 as a potential target in advanced breast cancer: a systematic review, meta-analysis, and bioinformatics validation.Scientific reports · 2023Pooled it
- Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.Bioorganic chemistry · 2021Pooled it
- Trial
- Multitarget Drug Design for Cardiovascular Disease: Bridging Chemistry and Medicine.ChemMedChem · 2026Review
- Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Design, Synthesis,Molecules (Basel, Switzerland) · 2026Article
- Research Progress and Application Prospects of Bioaffinity Chromatography in Screening Cardiotoxic Components of Chinese Herbal Medicines.ACS omega · 2026Review
- Novel 3-Methoxypropanamide Derivatives as Potential Antiseizure and Antinociceptive Agents: Experimental Evidence from In Vitro and In Vivo Studies.Journal of medicinal chemistry · 2026Article
- Plant-derived soft electrophiles upregulate pro-resolving oxylipins in a paraquat-inducedbioRxiv : the preprint server for biology · 2026Article
- Integrating Phytochemical Bioactivity and Glycemic Risk to Evaluate Fruits for Type 2 Diabetes Management: A Korean Market Perspective.Foods (Basel, Switzerland) · 2026Article
- Polynitrogen-containing compounds as multi-target sEH/FAAH inhibitors: Structure-activity relationship and pharmacological studies.Bioorganic & medicinal chemistry · 2026Article
- Black Gold in Medicine: Rediscovering the Pharmacological Potential.Molecules (Basel, Switzerland) · 2026Review
- Terminus-specific antibody development and bioanalytical assay validation to quantify active DR10624 in pharmacokinetic studies.Frontiers in pharmacology · 2026Article
- Article
- Shaping the future one slice at a time: How 3D organotypic tumour slice models are driving drug discovery in ovarian cancer.Translational oncology · 2026Review
- In Vitro Assessment of the Combined Activity of Amphotericin B and CuTropical medicine and infectious disease · 2025Article
- Elucidation of a Novel Dual Binding Site on Tubulin: Theoretical Insights and Prospective Hybrid Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Design and biological evaluation of mesalamine-NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy.Scientific reports · 2025Article
- Dually Decorated Palmitate-Containing Lipid Nanoparticles for the Targeted Delivery of siRNAs against HER2 and Hsp27 in HER2Journal of medicinal chemistry · 2025Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.